WASHINGTON (dpa-AFX) - Alexion Pharmaceuticals, Inc. (ALXN) announced the company now expects 2016 total revenues to be at the low end of previously guided range of $3.05 to $3.10 billion, primarily due to increased macroeconomic weakness in Latin America, partially offset by an increase in Strensiq revenues and the strengthening of foreign currencies. R&D and SG&A expenses are expected to be at the high end of guidance.
Alexion expects 2016 non-GAAP EPS to be at the low end of the previously guided range of $5.00 to $5.20 per share.
Copyright RTT News/dpa-AFX